Literature DB >> 8840224

Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model.

J Gong1, R Larsson, K N Ekdahl, T E Mollnes, U Nilsson, B Nilsson.   

Abstract

We describe here a model for the study of blood/surface and blood/air interaction as encountered in cardiopulmonary bypass (CPB) circuits. Polyethylene tubing was filled with serum or blood and closed end to end into loops whereby the volume of the remaining air bubble was inversely varied with respect to that of the fluid. The loops were rotated vertically in a water bath at 37 degrees C. The profiles of C3a, iC3, and TCC generation were similar to those observed at surgery, involving CPB. Soluble heparin and heparan sulfate inhibited both C3a and TCC formation, but surface-conjugated heparin had only a minor effect. Binding of C3 and/or C3 fragments to the heparin surface was much reduced compared to the amine matrix to which heparin was linked, but compared with the polyethylene surface the effect was less pronounced. These data suggest that, in addition to the biomaterial surface, the blood-gas interface seems to play an important role in the activation of complement and that this activation is inhibitable by high concentrations of soluble glucose aminoglycans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840224     DOI: 10.1007/bf01541228

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

Review 1.  The response of human platelets to activated components of the complement system.

Authors:  P J Sims; T Wiedmer
Journal:  Immunol Today       Date:  1991-09

2.  Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces.

Authors:  S K Law; N A Lichtenberg; R P Levine
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

3.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.

Authors:  K J Gadd; K B Reid
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

4.  Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.

Authors:  F Maillet; M D Kazatchkine; D Glotz; E Fischer; M Rowe
Journal:  Mol Immunol       Date:  1983-12       Impact factor: 4.407

5.  Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass.

Authors:  A M Gillinov; P A DeValeria; J A Winkelstein; I Wilson; W E Curtis; D Shaw; C G Yeh; A R Rudolph; W A Baumgartner; A Herskowitz
Journal:  Ann Thorac Surg       Date:  1993-03       Impact factor: 4.330

6.  Generation of iC3 at the interface between blood and gas.

Authors:  K Nilsson Ekdahl; B Nilsson; M Pekna; U R Nilsson
Journal:  Scand J Immunol       Date:  1992-01       Impact factor: 3.487

7.  Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig.

Authors:  L Nilsson; K E Storm; S Thelin; L Bagge; J Hultman; J Thorelius; U Nilsson
Journal:  Artif Organs       Date:  1990-02       Impact factor: 3.094

8.  Complement activation during cardiopulmonary bypass: comparison between the use of large volumes of plasma and dextran 70.

Authors:  O J Mellbye; S S Frøland; P Lilleaasen; J L Svennevig; T E Mollnes
Journal:  Eur Surg Res       Date:  1988       Impact factor: 1.745

9.  A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3.

Authors:  B Nilsson; K E Svensson; M Inganäs; U R Nilsson
Journal:  J Immunol Methods       Date:  1988-03-16       Impact factor: 2.303

10.  Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.

Authors:  M D Kazatchkine; D T Fearon; D D Metcalfe; R D Rosenberg; K F Austen
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

View more
  13 in total

1.  Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood.

Authors:  L Moberg; O Korsgren; B Nilsson
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

2.  A new method for incorporating functional heparin onto the surface of islets of Langerhans.

Authors:  Sanja Cabric; Torsten Eich; Javier Sanchez; Bo Nilsson; Olle Korsgren; Rolf Larsson
Journal:  Tissue Eng Part C Methods       Date:  2008-06       Impact factor: 3.056

3.  Preclinical evaluation of innate immunity to baculovirus gene therapy vectors in whole human blood.

Authors:  Lindsay J Georgopoulos; Graciela Elgue; Javier Sanchez; Vincent Dussupt; Paola Magotti; John D Lambris; Thomas H Tötterman; Norman J Maitland; Bo Nilsson
Journal:  Mol Immunol       Date:  2009-08-08       Impact factor: 4.407

4.  Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.

Authors:  Robert Silasi-Mansat; Hua Zhu; Narcis I Popescu; Glenn Peer; Georgia Sfyroera; Paola Magotti; Lacramioara Ivanciu; Cristina Lupu; Tom E Mollnes; Fletcher B Taylor; Gary Kinasewitz; John D Lambris; Florea Lupu
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

Review 5.  Innate immunity activation on biomaterial surfaces: a mechanistic model and coping strategies.

Authors:  Kristina N Ekdahl; John D Lambris; Hans Elwing; Daniel Ricklin; Per H Nilsson; Yuji Teramura; Ian A Nicholls; Bo Nilsson
Journal:  Adv Drug Deliv Rev       Date:  2011-07-08       Impact factor: 15.470

6.  Preparatory studies of composite mesenchymal stem cell islets for application in intraportal islet transplantation.

Authors:  Ida Rasmusson Duprez; Ulrika Johansson; Bo Nilsson; Olle Korsgren; Peetra U Magnusson
Journal:  Ups J Med Sci       Date:  2010-11-04       Impact factor: 2.384

7.  A novel model for studies of blood-mediated long-term responses to cellular transplants.

Authors:  Maria Hårdstedt; Susanne Lindblom; Jaan Hong; Bo Nilsson; Olle Korsgren; Gunnar Ronquist
Journal:  Ups J Med Sci       Date:  2014-10-17       Impact factor: 2.384

8.  Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood.

Authors:  Shan Huang; Kerstin Sandholm; Nina Jonsson; Anders Nilsson; Anders Wieslander; Gunilla Grundström; Viktoria Hancock; Kristina N Ekdahl
Journal:  Clin Kidney J       Date:  2014-12-01

9.  Bioengineering of improved biomaterials coatings for extracorporeal circulation requires extended observation of blood-biomaterial interaction under flow.

Authors:  Kris N J Stevens; Yvette B J Aldenhoff; Frederik H van der Veen; Jos G Maessen; Leo H Koole
Journal:  J Biomed Biotechnol       Date:  2007

Review 10.  Obstacles in haemocompatibility testing.

Authors:  W van Oeveren
Journal:  Scientifica (Cairo)       Date:  2013-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.